There are currently 971 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Urology San Antonio, San Antonio, Texas
Conditions: Bladder Cancer
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Texas Spine Care Center, San Antonio, Texas
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
NCT05566717
Recruiting
Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale
Gender:
All
Ages:
18 years and above
Trial Updated:
09/30/2022
Locations: Medical Center Ophthalmology Associates, San Antonio, Texas
Conditions: Diabetic Retinopathy, Neurotrophic Keratitis
Register for Updates
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
NCT04375813
Recruiting
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without advers... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2022
Locations: South Texas Veterans Health Care System (recruiting for treatment at UT Health San Antonio), San Antonio, Texas +1 locations
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: American Research Corporation, San Antonio, Texas +2 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
NCT03988855
Recruiting
This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV infusion in subjects with CDI. The study will be conducted in 2 subsequent parts. In Part 1 of the study, 10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. In Part 2 of the study, up to 30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. In both parts of the study, treatment i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2022
Locations: Southern Star Research Institute, LLC., San Antonio, Texas
Conditions: Clostridium Difficile (C. Difficile)
Register for Updates
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Gender:
All
Ages:
Between 6 months and 36 months
Trial Updated:
08/01/2022
Locations: Benchmark Research, San Antonio, Texas
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
NCT04678908
Recruiting
This is a multicenter, open-label, dose escalation and expansion study. During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0025. The phase I study will enroll up to 154 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2022
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Tumor, Subjects
Register for Updates
Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction
NCT03678467
Recruiting
EpiBone-Craniomaxillofacial (EB-CMF) is an autologous, anatomically shaped bone graft created specifically for the patient's defect, using the patients own adipose-derived mesenchymal stem cells. This first in human trial is designed specifically to assess the safety of EB-CMF clinically. Although secondary measures of graft efficacy are being assessed, the primary focus will be on Adverse Events stemming from graft implantation.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/24/2022
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Mandible Tumor, Mandibular Injuries, Mandible; Deformity
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: UT Health Science Center, San Antonio, San Antonio, Texas
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
NCT05205070
Recruiting
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2022
Locations: Site 10-108, San Antonio, Texas
Conditions: Alopecia Areata
Register for Updates
Study of Endothelial Cell Condition After Cataract Surgery Performed Using Capsulorhexis or ZEPTO
NCT04882189
Recruiting
This study will use images of the subjects' corneal endothelium obtained using non-invasive specular microscopy to obtain corneal endothelial cell density, the coefficient of variation in endothelial cell size, and the percentage of hexagonal endothelial cells following routine cataract surgery performed using the standard method of manual capsulorhexis compared to cataract surgery performed using Zepto Precision Capsulotomy System.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/08/2022
Locations: UltraVision, San Antonio, Texas
Conditions: Endothelial Cell Density Loss
Register for Updates